Posted by Michael Wonder on 29 Jun 2024
Abdera Therapeutics announces FDA fast track designation for ABD-147, a next generation precision radiopharmaceutical therapy, for the treatment of patients with extensive-stage small cell lung cancer
27 June 2024 - Abdera Therapeutics today announced that the US FDA has granted fast track designation to ABD-147 for the treatment of patients with extensive stage small cell lung cancer who have progressed on or after platinum-based chemotherapy.
ABD-147 is a next generation precision radiopharmaceutical biologic therapy designed to deliver Actinium 225 to solid tumours expressing DLL3, a protein found on the surface of neuroendocrine tumours, but rarely expressed on the surface of normal cells or tissues.
